Table 3.
VOYAGER PAD trial: overall results comparing rivaroxaban 2.5 mg twice-daily with placebo on a background of antiplatelet therapy
| Outcome | Rivaroxaban 2.5 mg twice-daily | Placebo twice-daily | HR (95% CI) |
|---|---|---|---|
| N = 3286 | N = 3278 | ||
| Acute limb ischaemia, major amputation for vascular causes, myocardial infarction, ischaemic stroke, or CV death | 508 (15.5%) | 584 (17.8%) | 0.85 (0.76–0.96) |
| Acute limb ischaemia | 155 (4.7%) | 227 (6.9%) | 0.67 (0.55–0.82) |
| Major amputation for vascular causes | 103 (3.1%) | 115 (3.5%) | 0.89 (0.68–1.16) |
| Myocardial infarction | 131 (4.0%) | 148 (4.5%) | 0.88 (0.70–1.12) |
| Ischaemic stroke | 71 (2.2%) | 82 (2.5%) | 0.87 (0.63–1.19) |
| CV death | 199 (6.1%) | 174 (5.3%) | 1.14 (0.93–1.40) |
| Mortality | 321 (9.8%) | 297 (9.1%) | 1.08 (0.92–1.27) |
| Venous thromboembolism | 25 (0.8%) | 41 (1.3%) | 0.61 (0.37–1.00) |